Influential Analyst Rating Changes: Allscripts Healthcare Solutions, Inc. (MDRX), UDR, Inc. (UDR)

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) tinted gains of +0.35% (+0.04 points) to US$11.41. The volume of 2.65 Million shares climbed up over an trading activity of 2.63 Million shares. EPS ratio determined by looking at last 12 month figures is -0.29. Over the same time span, the stock marked US$16.13 as its best level and the lowest price reached was US$8.54. The corporation has a market cap of US$1.99 Billion.

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)’s earnings per share has been growing at a 24.8 percent rate over the past 5 year when average revenue increase was noted as 4.5 percent. The return on equity ratio or ROE stands at -0.5 percent while most common profitability ratio return on investment (ROI) was -4 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -0.3 percent and possesses 41.7 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 6 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 12 think it is Hold. Recently, analysts have updated the overall rating to 2.35. 4 analysts recommended Overweight these shares while 1 recommended Underweight, according to FactSet data.

UDR, Inc. (NYSE:UDR) is worth US$11.03 Billion and has recently risen 0.35% to US$40.15. The latest exchange of 1.63 Million shares is below its average trading activity of 2.04 Million shares. The day began at US$39.99 but the price moved to US$39.82 at one point during the trading and finally capitulating to a session high of US$40.2. The stock tapped a 52-week high of US$42.98 while the mean 12-month price target for the shares is US$42.68.

Currently, the stock carries a price to earnings ratio of 146.53, a price to book ratio of 4.22, and a price to sales ratio of 10.68. For the past 5 years, the company’s revenue has grown 6.8%, while the company’s earnings per share has grown 24.8%. With an institutional ownership near 97.9%, it carries an earnings per share ratio of 0.27.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 18 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 1 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.82.